Investigating a new treatment for Alzheimer's disease using mixed receptor modulators
Official title: Dopamine and Sigma Receptor Mixed Modulators for the Treatment of Alzheimer's Disease
Funded at Southern Illinois Univ at Edwardsville · NIH-11101297 · Data updated 2026-11-12
This study is looking at a new treatment for Alzheimer's disease using a small molecule called AM73, which might help improve brain function and behavior in mice, with hopes that it could lead to better options for people living with Alzheimer's.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Southern Illinois Univ at Edwardsville NIH-funded |
| Lab location | 1 site (Edwardsville, United States) |
| Project start | June 4, 2024 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $144,500 |
| NIH project number | 5R16NS140308-02 |
| Project ID | NIH-11101297 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 65 and older who are experiencing cognitive decline or have been diagnosed with Alzheimer's disease.
✕Less likely to help
Patients under the age of 65 or those without cognitive decline or Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on developing a new treatment for Alzheimer's disease (AD) by exploring a small molecule called AM73 that targets specific brain receptors involved in cognitive decline. The study will evaluate the effects of chronic treatment with AM73 in a mouse model, assessing its impact on behavior and brain function. By analyzing changes in key brain regions associated with AD, the research aims to provide insights into how this novel approach could improve symptoms of the disease. The findings could lead to new therapeutic options for patients suffering from Alzheimer's.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that improves cognitive function and quality of life for Alzheimer's patients.
How similar studies have gone: While the approach of using mixed receptor modulators is novel, similar studies targeting brain receptors have shown promise in other neurological conditions.
Where this research is happening
-
Southern Illinois Univ at Edwardsville
Edwardsville, United States Active
Researchers
- Principal investigator: Witt, Ken a — Southern Illinois Univ at Edwardsville
- Study coordinator: Witt, Ken a
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.